GlycoNex EBIT per Employee

What does GlycoNex do? GlycoNex, Inc. develops anti-cancer monoclonal antibodies and bio-similar drugs, offering licensing for monoclonal antibody targets and carbohydrate antigen and protein drug services. The company targets domestic and Asian markets, distributing its products through these regions. Revenue comes from drug development, licensing agreements, and service provision for antibody targets and related biotech solutions. GlycoNex focuses on anti-cancer monoclonal antibody new drugs and bio-similar drugs, with services including carbohydrate antigen and protein drug related offerings. The firm serves domestic and overseas markets in Asia, generating income from product development, licensing, and specialized biotech services. Its business model relies on developing and commercializing innovative cancer treatments and related services in key Asian markets. The company's revenue streams include the development of anti-cancer monoclonal antibody new drugs, bio-similar drugs, and the licensing of monoclonal antibody targets. Services related to carbohydrate antigen and protein drug solutions are also part of the business, distributed across domestic and Asian markets to generate income from pharmaceutical innovation and biotech service contracts. GlycoNex is one of the most popular companies on Eulerpool.